Evidence map›Paper›PMID 37798644›Full record

ArticleBMC infectious diseases2023

Incidence and risk factors of neonatal bacterial infections: a community-based cohort from Madagascar (2018-2021).

Ines Devred, Lison Rambliere, Perlinot Herindrainy, Lovarivelo Andriamarohasina, Aina Harimanana, Frederique Randrianirina, Elisoa Hariniaina Ratsima, Delphine Hivernaud, Elsa Kermorvant-Duchemin, Zafitsara Zo Andrianirina and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Changes in the epidemiology of neonatal bacteremia during the COVID-19 pandemic in Wuhan, China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Ines DevredCESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Lison RambliereCESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Perlinot HerindrainyEpidemiology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Lovarivelo AndriamarohasinaEpidemiology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Aina HarimananaEpidemiology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Frederique RandrianirinaCentre de biologie clinique, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Elisoa Hariniaina RatsimaCentre de biologie clinique, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Delphine HivernaudHôpital Necker-Enfants malades, Department of Neonatal medicine, AP-HP, Université Paris Cité, Paris, France.
Elsa Kermorvant-DucheminHôpital Necker-Enfants malades, Department of Neonatal medicine, AP-HP, Université Paris Cité, Paris, France.
Zafitsara Zo AndrianirinaPeadiatric Ward, Centre Hospitalier de Soavinandriana, Antananarivo, Madagascar.
Armya Youssouf AbdouCESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Elisabeth Delarocque-AstagneauCESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Didier GuillemotCESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Tania Crucitti *Experimental Bacteriology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Jean-Marc Collard *Experimental Bacteriology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Bich-Tram HuynhCESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France. bich-tram.huynh@pasteur.fr.
Institut Pasteur de Madagascar · MGUniversité Paris Cité · FRInserm · FRInstitut Pasteur · FRUniversité de Versailles Saint-Quentin-en-Yvelines · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies on neonatal severe bacterial infection are available in LMICs. Data are needed in these countries to prioritize interventions and decrease neonatal infections which are a primary cause of neonatal mortality. The BIRDY project (Bacterial Infections and Antimicrobial Drug Resistant among Young Children) was initially conducted in Madagascar, Senegal and Cambodia (BIRDY 1, 2012-2018), and continued in Madagascar only (BIRDY 2, 2018-2021). We present here the BIRDY 2 project whose objectives were (1) to estimate the incidence of neonatal severe bacterial infections and compare these findings with those obtained in BIRDY 1, (2) to identify determinants associated with severe bacterial infection and (3) to specify the antibiotic resistance pattern of bacteria in newborns.

methodsThe BIRDY 2 study was a prospective community-based mother and child cohort, both in urban and semi-rural areas. All pregnant women in the study areas were identified and enrolled. Their newborns were actively and passively followed-up from birth to 3 months. Data on clinical symptoms developed by the children and laboratory results of all clinical samples investigated were collected. A Cox proportional hazards model was performed to identify risk factors associated with possible severe bacterial infection.

findingsA total of 53 possible severe bacterial infection and 6 confirmed severe bacterial infection episodes were identified among the 511 neonates followed-up, with more than half occurring in the first 3 days. For the first month period, the incidence of confirmed severe bacterial infection was 11.7 per 1,000 live births indicating a 1.3 -fold decrease compared to BIRDY 1 in Madagascar (p = 0.50) and the incidence of possible severe bacterial infection was 76.3, indicating a 2.6-fold decrease compared to BIRDY 1 in Madagascar (p < 0.001). The 6 severe bacterial infection confirmed by blood culture included 5 Enterobacterales and one Enterococcus faecium. The 5 Enterobacterales were extended-spectrum β-lactamases (ESBL) producers and were resistant to quinolones and gentamicin. Enterococcus faecium was sensitive to vancomycin but resistant to amoxicillin and to gentamicin. These pathogns were classified as multidrug-resistant bacteria and were resistant to antibiotics recommended in WHO guidelines for neonatal sepsis. However, they remained susceptible to carbapenem. Fetid amniotic fluid, need for resuscitation at birth and low birth weight were associated with early onset possible severe bacterial infection.

conclusionOur results suggest that the incidence of severe bacterial infection is still high in the community of Madagascar, even if it seems lower when compared to BIRDY 1 estimates, and that existing neonatal sepsis treatment guidelines may no longer be appropriate in Madagascar. These results motivate to further strengthen actions for the prevention, early diagnosis and case management during the first 3 days of life.

Indexed as

Bacterial InfectionsCommunicable DiseasesNeonatal SepsisAnti-Bacterial AgentsBacteriaChildChild, PreschoolFemaleGentamicinsHumansIncidenceInfant, NewbornMadagascarPregnancyProspective StudiesRisk FactorsAnti-Bacterial AgentsGentamicinsAntibiotic resistanceMadagascarNeonatalSevere Bacterial Infection

Identifiers

PMID37798644
PMCPMC10552278
OpenAlexW4387373352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.